Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer

Cynthia I Tchio Mantho, Adriana Harbuzariu, Ruben R Gonzalez-Perez

Because pancreatic cancer (PC) historically has had poor prognosis and five year survival rates, it has been intensely investigated. Analysis of PC incidence and biology has shown a link between different risk factors such as smoking, alcoholism, and obesity and disease progression. Important factors affecting PC include the epigenomic changes driven by DNA methylation and histone acetylation, and actions of microRNA inducing oncogenic or tumor suppressor effects. Studies have identified markers whose dysregulation seem to play important roles in PC progression. PC markers involve classical histone deacetylases (HDAC), PC stem cell (PCSC), and leptin. In this review, we discuss the role of several PC biomarkers, and the potential crosstalk between HDAC, microRNA, and leptin. Data analysis suggests that HDAC-microRNA-leptin signaling crosstalk may be a new target for PC therapy.

**Key words:** Pancreatic Cancer; MicroRNA; Histone deacetylase

Received: January 13, 2017  
Peer-review started: January 16, 2017  
First decision: February 20, 2017  
Revised: March 28, 2017  
Accepted: April 18, 2017  
Article in press: April 19, 2017  
Published online: June 10, 2017

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** Dr. Ruben R Gonzalez-Perez, Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Hugh Gloster Bldg., Room 329, Atlanta, GA 30310, United States. rgonzalez@msm.edu  
Telephone: +1-404-7521581  
Fax: +1-404-7521179

**Support by:** NIH/NCI, No. 1R41CA183399-01A1; Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP), No. DODXWH-13-1-0382; the DoD W81XWH-13-1-0382; NIH/SHIR1R41CA183399-01A1; Pilot Project Award from MSM/Tuskegee University/UB Cancer Center Partnership grant 5U54CA118638; PC SPORE Grant from UAB to RRG; National Institute on Minority Health and Health Disparities (NIMHD) of NIH under award number 5S21MD00101, and facilities and support services at MSMS (1G12RR026250-03; NIH RR 03034 and 1C06 RR18386); and The Calvin Johnson Jr. Foundation Pancreatic Cancer Research Scholarship to Cynthia I Tchio Mantho.
deacetylases; Pancreatic cancer stem cell markers; Leptin; Obesity

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Pancreatic cancer has no targeted therapy. Obesity is a risk factor for pancreatic cancer, characterized by high levels of leptin. In this review, we discuss the potential crosstalk between histone deacetylases, microRNA, and leptin in disease progression. Crosstalk among these molecules increases proliferation, survival, cancer stem cells and resistance to chemotherapy. The potential relationships between these molecules are analyzed using data from the Cancer Genome Atlas and the Pathway Studio Platform. The crosstalk among these molecules could be a novel target for pancreatic cancer prevention or treatment, particularly in obese patients that show elevated levels of leptin.

INTRODUCTION

Pancreatic cancer (PC) is a malignant disease, which is difficult to treat. It is a silent disease that can go undetected for long periods of time; however, when diagnosed, it is often in advanced stages (III or IV)[3]. PC incidence and mortality rates vary across different racial/ethnic groups, with the highest rates found in African Americans, and the lowest in Asian Americans/Pacific Islanders. Moreover, PC incidence rate is higher in African Americans when compared to European Americans at every age[5]. Risk factors for the development of PC include tobacco usage, continuous exposure to such chemicals as dyes and pesticides, family history, age, epigenetic changes, and obesity[1-9]. The best outcomes from PC treatments are obtained after complete surgical resection, with no residual disease; this can improve 5 year survival, but only from 5% to about 20%-25%[6]. Even patients who are eligible for surgical treatment with tumor free margins often experience recurrence and eventually require palliative treatment[7,8]. Surgical resection of PC is performed on patients with locally advanced or borderline resectable tumors. Improved outcomes may be achieved with a multimodal approach, combining neo-adjuvant chemotherapy with radiation therapy and surgery. Adjuvant therapy includes 5-fluorouracil (5-FU) or capecitabine; gemcitabine induction followed by concomitant chemoradiation with either gemcitabine or S-FU; FOLFIRINOX (an aggressive chemotherapeutic regimen, including several chemotherapeutic agents) or gemcitabine-Nab paclitaxel (albumin bound) with or without subsequent chemoradiation. For patients with metastatic PC, the treatment options are very limited. It mainly consists of palliative care (pain and nutrition management), as well as chemotherapy. The chemotherapy regimens for metastatic PC (gemcitabine alone or in combination with other agents for example, FOLFIRINOX, Nab-paclitaxel) have only modest results, improving the survival of these patients by only a few months[9,10].

Important factors affecting PC are the changes in the epigenome driven by DNA methylation and histone acetylation. Epigenetic changes are alterations in gene expression or cellular phenotype that occur without changes in the DNA sequence. Some of the epigenetic changes are DNA methylation and histone acetylation. This last process is characterized by the addition of acetyl groups to the lysine residues of the histones via histone acetyltransferases (HAT). Histone acetylation is essential to gene regulation, and is usually associated with the relaxed form of chromatin. Lysine residues can also be deacetylated by histone deacetylases (HDAC). These enzymes are involved in cancer progression by increasing proliferation, survival and resistance to chemotherapy of cancer cells as well as angiogenesis[11-15].

The dysregulation of microRNAs is another factor involved in cancer progression[16-18]. MicroRNAs (miRNA or miR) are noncoding endogenous RNAs that regulate protein expression. Accumulating data show important relationships between dysregulated microRNAs and cancer[16-19]. The effect that miRNAs dysregulation has on the cancer cells determines whether these molecules are considered oncogenics or tumor suppressors. Oncogenic microRNAs promote cancer development through various signaling mechanisms while tumor suppressor miRNAs have contrary effects and their expression is decreased in cancer[19,20]. There are many oncogenic microRNAs (e.g., miR21) that have been reported to play a role in cancer progression[20-23]. Furthermore, the decreased expression of tumor suppressor miR200 family has been associated with PC progression[24,25].

Obesity is one the most observed risk factors for cancer progression. Obesity is a growing pandemic, and is associated with more than 100000 incidences of various cancers in the United States, particularly breast, colon, endometrium and PC[26-28]. Obesity is characterized by the accumulation of excessive body fat, and a body mass index (BMI) value greater than 30. Obesity is also characterized by high levels of leptin, which has been consistently associated with many cancers, including PC[29-33]. Preliminary analyses suggest that leptin could affect the expression of microRNA and HDAC in PC.

Because of the absence of targeted therapies for obese PC patients, there is a need to better understand the mechanisms behind the disease progression in order to develop better treatment strategies. Thus, in this review, we will discuss the potential relationships between HDAC, microRNA, cancer stem cells, and leptin.
signaling in PC.

PC TYPES

There are two types of PC - those that comprise tumors arising from the endocrine pancreatic cells and those that arise from the exocrine pancreatic cancers. Cancers of the endocrine pancreas are rare and represent less than 4% of all PC cases\(^1\). Pancreatic Adenocarcinoma (PA) is the most common type of PC and usually begins in the ducts of the pancreatic glands. PC has been recently classified into four main subtypes based on their genomic analysis (e.g., squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine or ADEX)\(^{34}\).

PC squamous subtype is characterized by four core genes programs involved in inflammation, hypoxia response, metabolic reprogramming, transforming growth factor-\(\beta\) (TGF-\(\beta\)) signaling, autophagy, and upregulated expression of TP63A\(^{\alpha}\) and its target genes\(^{34}\). The pancreatic progenitor subtype is characterized by the transcriptional networks of pancreatic and duodenal homeobox-1 (PDX1), motor neuron and pancreas homebox-1 (MNX1), hepatocyte nuclear factor-4-\(\alpha\) (HNF4A), hepatocyte nuclear factor-1-\(\beta\) (HNF1B), hepatocyte nuclear factor-1-\(\alpha\) (HNF1A), forkhead box-A2 (FOXA2), forkhead box-A3 (FOXA3), and hairy and enhancer of split-1 (HES1) transcription factors\(^{34,35}\). The immunogenic subtype of PC is characterized by changes in the programs of immune genes that include antigen presentation, CD4\(^{+}\) and CD8\(^{+}\) T cells, and toll-like receptor and B cell signaling pathways\(^{36}\). ADEX is characterized by the upregulation of transcriptional networks of both exocrine and endocrine lineages that are important in later stages of pancreatic development and differentiation\(^{34}\).

In addition, some hereditary factors play roles in the development of PC. Individuals with a high risk of developing PC can be divided into underlying gene defect, like cyclin-dependent kinase Inhibitor 2A (CDKN2A), breast cancer gene 1 and 2 (BRCA1/2), partner and localizer of BRCA2 (PALB2), and serine/threonine kinase 11 (STK11) mutations\(^{35,36}\). In a study performed by Vasen et al\(^{36}\), the long-term outcome of prospective surveillance of a large group of CDKN2A/p216-Leiden carriers and, BRCA1/2 and PALB2 mutation carriers, and individuals at risk (IARs) for familial PC (FPC) was evaluated. The main goal of the study was to determine whether or not surveillance will lead to the detection of early stage PC or the detection of relevant precursors lesions (PRLs) as well as to assess if their program leads to improvements in prognosis\(^{36}\).

Based on the surveillance, it was determined that PRLs were more frequent in patients with FPC than those with CDKN2A/p216-Leiden mutation\(^{36}\). The surveillance study also reveals that the resection of screen detected PC with CDKN2A/p216-Leiden mutation carriers was 75%, which is higher than that reported for patients with sporadic PC (15%-20%)\(^{36}\). Overall, the study demonstrated that the surveillance of CDKN2A mutation carriers was successful for the detection of PC at the resectable stage\(^{36}\).

PC BIOMARKERS

PC is generally diagnosed when approximately 30% of patients present a locally advanced disease\(^1\). Because there is no effective treatment for advanced PC, this disease should be detected in the early stages when treatment could significantly increase the percentage of patients five years of survival. The best way to PC early diagnosis would be via the usage of screening biomarkers with high specificity and sensitivity. Currently, the most established and used biomarker is CA19-9. However, CA19-9 detection is not highly specific for PC, as it can also be detected in colorectal cancer, stomach, and biliary epithelium and chronic pancreatitis\(^{36}\).

A vast array of other PC biomarkers has been investigated, but so far none are as yet widely used clinically. It has recently been shown that exosomes could potentially impact on the pathogenesis of PC through the modulation of tumor growth, microenvironment, and immune response. This suggests that exosomes could be used as biomarkers for PC\(^{39}\). An additional PC marker could be the leptin receptor, OB-R, which has been detected in PC cell lines\(^{40}\). Moreover, OB-R expression was positively correlated with the matrix metalloproteinase-13 (MMP-13) in human PC tissues. The increased expression of either OB-R or MMP-13 was significantly associated with lymph node metastasis; it also tends to be associated with the TNM stage in PC patients\(^{40}\).

Likewise, it has been proposed that the detection of PC cells in blood could be used as a surrogate for PC detection\(^{41,42}\). Circulating tumor cells (CTC) could be related to metastatic and more aggressive PC disease, according to the results from an international multicenter randomized study that included 79 patients. A subgroup of PC patients was screened for CTCs before the start of the chemotherapy, and after two months of treatment. Overall, CTC detection was found in 11% of PC patients and associated with poor tumor differentiation (\(P = 0.04\)), and with shorter overall survival (\(RR = 2.5, P = 0.01\)). Therefore, CTC detection might be a new way to detect PC\(^{38}\).

HISTONE DEACETYLASES IN PC

HDAC play a major role in the regulation of gene expression via epigenetics changes. HDAC catalyze the removal of an acetyl group, which stimulates chromatin condensation, thus suppressing transcription. Currently, 18 HDAC family members have been identified in the human genome, which are grouped into four classes (I - IV)\(^{43}\). HDAC are also classified into two major types: Sirtuins (SIRT) and classical HDAC. Classical HDAC include Classes I, II, and IV, whereas the sirtuins comprise Class III\(^{43,44}\) (Table 1). HDAC classes I, II, and IV are zinc dependent metalloproteins, while class III are nicotinamide adenine dinucleotide (NAD\(^{+}\)) dependent
enzymes. Class I HDAC family consists of HDAC 1, 2, 3, and 8. These enzymes are mainly located in the cellular nucleus. Class II HDAC family is divided into two groups - Classes II A and II B. These HDAC are mainly located in the cytoplasm, but can also be found in the nucleus, which is dependent on their phosphorylation status influencing their shuttle mechanism. Class II A HDAC family consists of HDAC 4, 5, 7, and 9; while subclass II B consists of HDAC 6 and 10. HDAC Class IV is only made of HDAC11 that is mainly located in the nucleus. Class III is composed of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7, which are located in the nucleus, cytoplasm, and mitochondria. Due to the role of HDAC in epigenetic regulations and their effect on chromatin structures, many studies have found them linked to cancer progression. The classical HDAC have been associated with cancer progression through the increase of proliferation, survival and resistance to chemotherapy of cancer cells, and angiogenesis. More studies suggest the roles of HDAC in PC progression. The use of HDAC inhibitors is a novel avenue toward targeted therapy for PC. Several HDAC inhibitors are currently under clinical trials for cancer-targeted treatment. However, currently there are only three FDA approved HDAC inhibitor drugs available [Vorinostat or Suberoylanilide Hydroxamic Acid (SAHA), Romidepsin (Depsipetide, ISTODAX), and Belinostat (Beleodaq)].

Vorinostat was the first FDA approved anti-HDAC drug. It is a hydroxamic acid based drug that inhibits Class I, II, IV HDAC by chelating the zinc cofactor. This drug shows apoptotic and anti-proliferative effects by modifying the expression of specific genes related to insulin-like growth factor-1 receptor signaling receptor (IGF-1R). The second FDA approved HDAC inhibitor drug is Romidepsin, which was effective in phase II clinical trials when used with gemcitabine for treatment of advanced PC. The third FDA approved HDAC inhibitor drug is Belinostat. It showed a dose dependent growth inhibitory or pro-apoptotic effects promoting cell cycle arrest at the G0/G1 or S phase transition. Additionally, positive results in the treatment of PC have been reported with the use of benzamide derivative HDAC inhibitor (Class I HDAC inhibitor MGCD0103) selective for Class I and IV HDAC. PC cell lines treated with MGCD0103 showed dose dependent growth arrest, apoptosis, and induction of p21, which mediated cell cycle arrest in G2/M phase.

**TUMOR SUPPRESSOR AND ONCOGENIC MiRNAS IN PC**

MicroRNAs (miRNA or miR) are noncoding endogenous RNAs of 14-24 nucleotides that have the ability to regulate protein expression at the post-transcriptional level. Many studies have found strong correlations between dysregulated microRNAs and cancer. According to the effect that miRNAs dysregulation has on the cancer cells, these molecules are considered oncogenic or tumor suppressors. There are many oncogenic microRNAs, such as miR1290, miR24, miR134, miR146a, miR378, miR484, miR628-3p, miR1825, and miR21 that have been reported to play a role in cancer progression. It was reported that serum levels of miR1290 distinguished patients with low-stage PC from controls better than CA19-9 levels. Furthermore, decreased expressions of miRNA34 and miR200 family have been associated with PC progression.

A study found that oncogenic miR21 was expressed in the early stage of PA. Furthermore, knockdown of miR21 using lentiviral vectors inhibited cell proliferation in PC derived cell lines. In addition, miR21 was found to protect PC cell from apoptosis, and its knockdown resulted in the activation of mitochondrial pathway apoptosis via the downregulation of Bcl9 (a protein involved in Wnt Pathway), upregulation of Bax, and induction of Bim. Targeting miR21 in vivo strongly inhibited PC growth, which led to the suggestion that simultaneous standard gemcitabine chemotherapy combined with miR21 targeting could improve the prognosis of PC.

MiRNA200 family consists of five members (miR200a, b, c and miR429, and miR141). In vitro studies suggested that miR200c expression was related to low cancer invasion. MiRNA200 activities include inhibition of epithelial-mesenchymal-transformation (EMT), repression of cancer stem cell (CSC) self-renewal and differentiation,

### Tumor Suppressor and oncoGenic MiRNAs in PC

MicroRNAs (miRNA or miR) are noncoding endogenous RNAs of 14-24 nucleotides that have the ability to regulate protein expression at the post-transcriptional level. Many studies have found strong correlations between dysregulated microRNAs and cancer. According to the effect that miRNAs dysregulation has on the cancer cells, these molecules are considered oncogenic or tumor suppressors. There are many oncogenic microRNAs, such as miR1290, miR24, miR134, miR146a, miR378, miR484, miR628-3p, miR1825, and miR21 that have been reported to play a role in cancer progression. It was reported that serum levels of miR1290 distinguished patients with low-stage PC from controls better than CA19-9 levels. Furthermore, decreased expressions of miRNA34 and miR200 family have been associated with PC progression.

A study found that oncogenic miR21 was expressed in the early stage of PA. Furthermore, knockdown of miR21 using lentiviral vectors inhibited cell proliferation in PC derived cell lines. In addition, miR21 was found to protect PC cell from apoptosis, and its knockdown resulted in the activation of mitochondrial pathway apoptosis via the downregulation of Bcl9 (a protein involved in Wnt Pathway), upregulation of Bax, and induction of Bim.

Targeting miR21 in vivo strongly inhibited PC growth, which led to the suggestion that simultaneous standard gemcitabine chemotherapy combined with miR21 targeting could improve the prognosis of PC.

MiRNA200 family consists of five members (miR200a, b, c and miR429, and miR141). In vitro studies suggested that miR200c expression was related to low cancer invasion. MiRNA200 activities include inhibition of epithelial-mesenchymal-transformation (EMT), repression of cancer stem cell (CSC) self-renewal and differentiation,
modulation of cell division and apoptosis, and involvement in chemoresistance. High level of miR200c correlated to better survival rates\(^{201}\), however, miR200a and miR200b, were hypomethylated and overexpressed in PC\(^{65}\). It has been suggested that targeting miRNA200 upregulation could improve PC prognosis if used together with the chemotherapeutic drug gemcitabine\(^{20}\). Indeed, treatment of PC cells with a curcumin analoge, CDF, improved gemcitabine effects by upregulating miR200 and downregulating miR-21 expression. These effects were found together with the downregulation of Akt, cyclooxygenase-2, prostaglandin E\(_2\), vascular endothelial growth factor, and nuclear factor-κB DNA binding activity, and induction of PTEN\(^{66}\).

Transcription factor ZFH family (ZEB1 and ZEB2)\(^{67}\) represses the expression of epithelial genes. miR200 members increased Notch activation by ZEB1 that regulates the expression of Jagged1 and the mastermind-like coactivators Mam2 and Mam3. Moreover, in PC and breast cancer cells, decreased miR200 expression was associated with increased Jag1 and ZEB1 levels\(^{68}\). Therefore, MiR200 inhibits EMT by interacting with ZEB1/2 and the Notch pathway, represses self-renewal and differentiation in CSCs, and is involved in the regulation of cell division and apoptosis\(^{44}\). In turn, ZEB1 suppresses the expression of miR200 family, which inhibits the translation of ZEB1 mRNA, resulting in the double-negative ZEB/miR200 feedback loop\(^{69}\). Additionally, in lung cancer Jagged2 inhibits the expression of miR200 family by induction of GATA transcription factors, which promotes tumor metastasis\(^{50}\).

We preliminarily analyzed PC biopsies using TCGA databank\(^{71}\). Data analysis shows higher miR21 expression compared with miR200 in PC (Figure 1). These data suggest that progression of PC could be positively associated with upregulation of miR21 and downregulation of miR200.

**Figure 1** IlluminaHiSeq miRNA expression of tumors tissues biopsies from pancreatic cancer patients. The data sets used were generated from the Cancer Genome Atlas Database\(^{72}\). The oncogenic miR21 is highly expressed in PC while there is a low expression of tumor suppressor miR200a/b/c (pancreatic cancer samples \(n = 45\)).

**PC STEM CELLS**

PC is usually diagnosed in the advanced stages after distant metastasis has already occurred in most cases. PC shows high frequency of local relapse, even after surgical resection. Treatment of PC via surgery and chemotherapy has historically had little success. Patients still have a poor survival rate with chemoresistance and reoccurrence of the disease as significant factors. These features of PC could be related to the action of PC stem cell (PCSC)\(^{72}\). Cancer stem cells are a small population that have the capacity to self-renew, and generate cells with identical tumorigenic potential that could also differentiate to form the bulk of the tumor cells, thereby contributing to the formation of heterogenic cellular composition of cancers\(^{55}\). A highly tumorigenic PCSC population (CD24\(^+\)CD44\(^+\)ESA\(^-\)) was described in PC for the first time by Li et al\(^{73}\) in a xenograft human model. PCSC are resistant to chemotherapy and contribute to tumor initiation, growth and metastasis\(^{74}\). PCSC were also identified as CD133\(^+\) population that is highly resistant to standard chemotherapy. A subgroup of these cells, CD133\(^+\)CXCR4\(^+\) was found to be involved in metastasis\(^{75}\).

C-Met, also known as hepatocyte growth factor receptor (HGFR), is an oncogene involved in the progression of cancer. C-Met was earlier described as a potential PCSC marker\(^{75-77}\). C-Met\(^+\) PCSC showed similar tumorigenic capacity as CD24\(^+\)CD44\(^+\)ESA\(^-\) population\(^{78-80}\). C-Met is a heterodimer that consist of an extracellular α-chain bound through a disulphide bridge to a transmembrane β-chain\(^{79}\). It is also a tyrosine kinase found in the cell membrane. HGF ligand binding to C-Met immunoglobulin like-domain induces C-Met dimerization, leading to autophosphorylation of the two tyrosine residues within the catalytic loop\(^{79}\). Subsequently, further autophosphorylation of two more tyrosine residues occurs in the C-terminal of C-Met receptors, which provides the platform for the recruitment of other molecular factors and signal conveyors like Grb2-associated binding protein 1 (Gab1). This provides a binding site for such SH2-containing effectors as SHP2, PLC\(_{γ}\), STAT3, Ras GTPase, and PI3K\(_{γ}\)\(^{79}\). With the emerging evidence of C-Met as a stem cell marker, some studies were able to identify part of the C-Met cell population that also expresses CD44, CD24, CD133, and ALDH1\(^{78,81}\). However, in a study c-Met\(^+\) PCSC produced tumors in 35% of cases when compared to PCSC CD133\(^+\) (16%) and CD24\(^+\) (25%) of cases\(^{78,80}\).

Notch signaling pathway is another factor that affects the maintenance of PCSC. Notch signaling pathway is a known regulator of the balance between cell self-renewal and cell differentiation. Abel et al\(^{82}\) found that components of Notch signaling were upregulated in PCSC. Moreover, the inhibition of Notch signaling pathway with gamma secretase inhibitors or Hes1 shRNA in PCSC reduced the percentage of PCSC and their ability to form tumorspheres. Furthermore, these authors found that the activation of Notch signaling pathway
using an exogenous peptide ligand greatly increased the percentage of PCSC and formation of tumorspheres[82].

Due to PCSC role in chemoresistance and disease reoccurrence, c-Met, CD44, CD24, CD133, and ALDH1 could potentially be used as biomarkers to detect PC progression. Moreover, developing therapies that would target PCSC markers could be adjuvant to the standard gemcitabine chemotherapy, which could improve PC survival rate[72,78].

**OBESITY AND PC**

Obesity is mainly the result of unhealthy diets and lifestyles, and has proven to be a contributing factor to higher risk and poor prognosis of cancer[1,83,84]. Several studies have examined the impact that obesity has on the overall survival rate of PC patients[84,85]. Some studies have determined that obesity in adulthood significantly shortened the overall survival of PC patients, whereas obesity at diagnosis was not associated with increased risk of death[84,85]. In another study, Sandini et al[86] assessed whether the evaluation of different body compartments and their relationships were associated with the development of major postoperative complications after pancreatoduodenectomy for cancer. It was found that the prevalence of sarcopenia (loss of muscle tissue related to aging) was 24.2%. Overall, sarcopenic obesity[86] and non-sarcopenic obesity[87] are strong predictors of major complications after pancreatoduodenectomy for cancer.

Obese PC patients have the poorest prognosis, and often develop chemoresistance. Obesity is recognized as a co-morbidity factor to cancer and there is great interest in understanding the mechanism linking this condition and cancer. In this regard, a recent study has found that obesity promoted desmoplasia associated with accelerated PC growth and impaired delivery/efficacy of chemotherapeutics through reduced perfusion in vivo[87]. Furthermore, the inhibition of angiotensin-II type-1 receptor (AT1) reversed obesity-augmented desmoplasia and PC growth and improved response to 5-FU chemotherapeutic in vivo[87]. In addition, clinical studies have shown that excess weight alters PC microenvironment to augment the crosstalk between cancer associated adipocytes, tumor associated neutrophils, and pancreatic stellate cells, which subsequently lead to increased tumor progression and survival[87].

**LEPTIN AND PC**

A potential link between obesity and PC could be the major adipokine leptin. A crosstalk between leptin and Notch (an embryonic signaling pathway altered in PC) has been reported in PC lines. Moreover, leptin induces PC tumourspheres formation and expansion of PCSC[81,88]. Leptin is a small cytokine secreted by adipose tissue that is coded by the obese (ob) gene. Leptin has been the most studied adipokine since it was first cloned in 1994[89]. Leptin is an adipokine that regulates appetite, energy intake and expenditure. Leptin plays many roles, some of which involve regulation of glucose homeostasis, growth response, reproduction and immune response[90]. The level of circulating leptin is proportional to total body fat. Obese patients exhibit high circulating levels of leptin due to leptin resistance[91]. Leptin is a pleiotropic adipokine and pro-inflammatory molecule that belongs to the family of helical cytokines. It is structurally similar to interleukin (IL)-6, IL-12, IL-15, prolactin, GH, oncostatin M, and granulocyte CSF[82].

Leptin receptor, OB-R, is a product of diabetic (db) gene that shows six alternatives spliced isoforms, including a long isoform (OB-RL, OB-Rb or LEPR) with full intracellular signaling capabilities, shorter isoforms with less biological activity (OB-Rs or OB-Ra) and a soluble isoform (OB-Re or sOB-R)[93,94]. Both the long and short isoforms of OB-R are expressed in PC cell lines[91]. Moreover, PC cells secreted leptin and expressed OB-R, which indicates a leptin autocrine/paracrine signaling loop could also affect tumor progression[95]. The binding of leptin to OB-R activates a cascade of events that promotes tumor progression and cancer cell survival[3,30,31]. Leptin binding to its receptor triggers an activation cascade of several canonical (JAK2/STAT3, MAPK, PI-3K/akt1) and non-canonical signaling pathways (p38MAK, JNK and AMPK)[96].

A nested case control study from three cohort studies of middle-aged adults showed that high pre-diagnostic circulating leptin concentrations were associated with an increased PC risk among those with longer follow-up[97]. In another study, Mendonsa et al[41] showed the contribution of obesity and leptin to PC growth by using an in vivo orthotopic murine PC model. These studies revealed the increase of tumor growth in diet-induced obese mice when compared to lean mice.

We have recently showed that leptin and Notch crosstalk could influence PC progression. Our data suggest that a functional leptin-Notch axis affects PC progression and expansion of cancer stem cells (PCSC) in PC cell lines (BxPC-3, MiaPaCa-2, Panc-1, AsPC-1) and derived tumorspheres. Leptin treatment increased cell cycle progression and proliferation, and the expression of Notch receptors, ligands and targeted molecules (Notch1-4, DLL4, JAG1, Survivin and Hey2), PCSC markers (CD24/CD44/ESA, ALDH, CD133, Oct-4), ABCB1 protein, as well as tumorsphere formation. PC has no targeted therapy and is mainly treated with chemotherapy, whose efficiency could be decreased by leptin and Notch activities. Thus, the leptin-Notch axis could be a novel therapeutic target, particularly for obese PC patients[95].

**LEPTIN-HDAC-MICRORNA-CANCER STEM CELLS CROSSTALK**

Resistance to leptin is observed in obese people who show high levels of leptin. Precise reasons explaining why some obese patients are leptin-resistant are not fully known. Some studies have suggested that leptin resistance could be due to abnormalities of the leptin molecule while others believe the resistance might be due to impairment of OB-R.
function or deficient leptin transport. Leptin is a known proliferation factor for cancer \[3,29,31,96\]. Analysis of data from Pathway Studio Platform shows that leptin signaling could promote PC through crosstalk mechanisms that involve PCSC, classical HDAC, oncogenic microRNA21, and tumor suppressor microRNA200a/b/c (Figure 2 and Supplemental Table 1).

A relationship between leptin signaling and miR21 in cutaneous wound healing was earlier reported \[98\]. The expression of miR21 and miR200 was previously linked to leptin hypothalamic signaling \[16,99,100\]. It was shown that the use of a pegylated leptin antagonist predisposed the rats to obesity and promoted leptin resistance in both hypothalamus and liver. RT-PCR data from these studies showed that miR200 was upregulated in rats treated with leptin antagonist \[16\]. Additionally, miR21 (oncogenic) and miR200 (tumor suppressor) have been shown to affect PC progression \[20,63\]. The potential relationships between leptin signaling and miR21 and miR200a/b/c regulation in PC are shown in Figure 2. Leptin signaling is involved in the crosstalk to many important oncogenic and tumor suppressor molecules. Previous studies have determined that leptin increases the expression of PCSC markers ALDH1 and CD44. Leptin has also been found to increase the expression of miR21 while the tumor suppressors miR200a, miR200b, and miR200c decrease the expression of OB-R. Interestingly, these tumor suppressors could also interact with some of PCSC markers (Met, ABCB1, CD44), which decrease their expression. In contrast, oncogenic miR21 increases the expression of ALDH1, ABCB1 and CD44 markers. With regard to the classical HDAC, only HDAC5 and HDAC4 markers. Regarding to the classical HDAC, only HDAC5 and HDAC4 were reported to be directly regulated by leptin signaling (Figure 2). However, leptin signaling could indirectly affect the expression of some of HDAC via microRNA or PCSC markers. Further analysis suggests that leptin increases the expression of miR21, which, in turn, could increase the expression of HDAC3. The combined action of these factors could promote cancer proliferation and the expression of an anti-differentiation phenotype (Supplemental Table 1).

Our published data show that leptin increased PCSC populations that correlated with growth of PC tumorspheres and resistance to gemcitabine \[88,95\]. Furthermore, leptin induced PCSC populations (CD24⁺CD44⁺ESA⁺, CD133⁺, ALDH⁺) in MiaPaCa-2 PC cells. Additionally, in Panc-1 cells, leptin increased mostly CD133⁺ PCSC. Moreover, leptin increased ABCB1 (an ATP Binding Transporter Protein linked
to chemoresistance) expression in PC tumorspheres\(^9\).\(^{195}\). These data suggest that leptin could play a role in the induction of PCSC and PC chemoresistance (Figure 3).

Several studies have found that classical HDAC are overexpressed in PC. Therefore, HDAC inhibition has become a potential target therapy for cancer\(^{101,102}\). Intriguingly, high expression of HDAC Class I and II in PC could be associated with obesity. It was found that the hypothalamic expression of classical HDAC was increased in obese mice fed a high fat diet\(^{100,103}\). Thus, it is possible that the increase in classical HDAC in obese mice could be related to leptin signaling. To initially explore the potential relationships between leptin signaling and HDAC, leptin effects on HDAC expression was preliminary determined in PC tumorspheres (Figure 3). Furthermore, preliminary data suggest that gemcitabine decreased the expression of HDAC2, HDAC3 and HDAC8 that was reverted by leptin. This suggests that leptin could affect the expression of HDAC in PC, which might be associated with chemoresistance.

CONCLUSION

PC is an aggressive disease commonly detected in its late stages, continues to show poor prognosis, and has no targeted treatment. Surgical tumor removal is the best option to eliminate PC, but only in limited number of cases. Therefore, most PC patients are treated with chemotherapeutics, but survival rates have historically been poor. Obesity is a modifiable risk factor of PC that is characterized by inflammation and high levels of the adipokine leptin, which is a cancer proliferation factor that can also contribute to chemoresistance. Studies have identified that the dysregulation of HDAC, miR21, miR200, leptin, and PCSC could play important roles in PC progression. Previous reports showed that leptin signaling can induce PC proliferation, PCSC expand and regulate miR21, miR200, and HDAC levels. Moreover, the analysis of data from PC biopsies (Cancer Genome Atlas\(^7\)) showed inverse expression profiles for miR21 and miRNA200 that suggests these molecules could be involved in PC development. Furthermore, HDAC, miRNA21/200, and leptin could have complex signaling crosstalk, according to Pathway Studio analysis. Therefore, leptin, miR21, miR200 and HDAC could be involved in PC progression. Thus, the potential crosstalk among these molecules could be a novel target for PC prevention or treatment, particularly in obese patients who show elevated levels of leptin.

ACKNOWLEDGMENTS

We thank Dr. Gale Newman for her assistance with the Pathway Studio software.

REFERENCES

1. American Cancer Society. Pancreatic Cancer American Cancer Society, 2015. [accessed 2015 Feb 18]. Available from: URL: http://www.cancer.org/cancer/pancreaticcancer/detail/diagnosis/pancreatic-cancer-what-is-pancreatic-cancer
2. Casari I, Falasca M. Diet and Pancreatic Cancer Prevention. Cancer (Basel) 2015; 7: 2309-2317 [PMID: 26610570 DOI: 10.3390/cancers7040892]
3. Dranka-Bojarowska D, Lekstan A, Olakowski M, Jablonska B, Lewinski A, Musialski P, Sobecky W, Kapalka A, Lampu P. The assessment of serum concentration of adiponectin and leptin in patients with pancreatic cancer and chronic pancreatitis. J Physiol Pharmacol 2015; 66: 653-663 [PMID: 26579571]
4. Mendonsa AM, Chalfant MC, Gorden LD, VanSaun MN. Modulation of the leptin receptor mediates tumor growth and migration of pancreatic cancer cells. PLoS One 2015; 10: e0126686 [PMID: 25919692]
5. Shi YQ, Yang J, Du P, Xu T, Zhuang XH, Shen JQ, Xu CF. Effect of Body Mass Index on Overall Survival of Pancreatic Cancer: A Meta-Analysis. Medicine (Baltimore) 2016; 95: e3305 [PMID: 27057903 DOI: 10.1097/MD.0000000000003305]
6. Smyth AG. A modified miniplate for use in malar complex fractures. Br J Oral Maxillofac Surg 1995; 33: 169-170 [PMID: 7654662 DOi: 10.1002/omb.22916]
7. Assafal V, Häuser N, Michalski C, Gillen S, Kleept F, Fries H. Palliative interventional and surgical therapy for unresectable pancreatic cancer. Cancers (Basel) 2011; 3: 652-661 [PMID: 24212634 DOI: 0.3390/cancers3010652]
8. Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP 2007; 8: 240-253 [PMID: 17356251]
9. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Buchet JB, Khemissa-Akouz F, Pérez-Vergé D, Delbaldo
Pancreatic cancer and lep...
Tchio Mantho CI et al. Pancreatic cancer and lepint crosstalk

10.1038/nature16965

35 Lynch HT, Lynch JF, Lanspa SJ. Familial pancreatic cancer. *Cancers* (Basel) 2010; 2: 1861-1883 [PMID: 24281205 DOI: 10.3390/cancers20201861]

36 Vassen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Caratto A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Masser M, Morreau H, Köppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. *J Clin Oncol* 2016; 34: 2010-2019 [PMID: 27114599 DOI: 10.1200/JCO.2015.64.0730]

37 Bhat K, Wang F, Ma Q, Li Q, Malkal S, Hsieh TC, WU E. Advances in biomarker research for pancreatic cancer. *Curr Pharm Des* 2012; 18: 2439-2451 [PMID: 23272502]

38 Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathioli C, Pierry JA, Hammel P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary Ca 07 study to the LAP 07 trial. *Ann Oncol* 2013; 24: 2057-2061 [PMID: 23676420 DOI: 10.1093/annonc/mdt176]

39 Robinson SM, Fan L, White SA, Charnley RM, Mann J. The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. *Int J Biochem Cell Biol* 2016; 75: 131-139 [PMID: 27017975 DOI: 10.1016/j.biocel.2016.03.009]

40 Fan Y, Gan Y, Shen Y, Cai X, Song Y, Zhao F, Yao M, Gu J, Tu H. Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production. *Oncotarget* 2015; 6: 16120-16134 [PMID: 25947972 DOI: 10.18632/oncotarget.3878]

41 Rückert F, Pilarsky C, Grützmacher R. Serum tumor markers in pancreatic cancer-recent discoveries. *Cancers* (Basel) 2010; 2: 1107-1124 [PMID: 24281109 DOI: 10.3390/cancers2021107]

42 Verma M. Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology. *Cancers* (Basel) 2010; 2: 1830-1837 [PMID: 24281203 DOI: 10.3390/cancers201830]

43 Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. *J Mol Biol* 2004; 348: 17-31 [PMID: 15058020 DOI: 10.1016/j.jmb.2004.02.006]

44 de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. *Biochem J* 2003; 370: 737-749 [PMID: 12429021 DOI: 10.1042/BJ20021221]

45 Marquard L, Gjerdum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. *Histopathology* 2008; 53: 267-277 [PMID: 18671804]

46 Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. *Oncogene* 2005; 24: 4531-4539 [PMID: 15806142 DOI: 10.1038/sj.onc.1208646]

47 Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. *BMC Cancer* 2012; 12: 226 [PMID: 22681698 DOI: 10.1186/1471-2407-12-226]

48 Wang B, Wang XB, Chen LY, Huang L, Dong RZ. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involved activation of TAK1-AMPK signaling axis. *Biochem Biophys Res Commun* 2013; 437: 1-6 [PMID: 23734198 DOI: 10.1016/j.bbrc.2013.05.090]

49 Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. *PLoS One* 2012; 7: e52095 [PMID: 23251689 DOI: 10.1371/journal.pone.0052095]

50 Debernardi S, Massat NJ, Radon TP, Sangaralingam A, Banissi A, Emnis DP, Dove T, Chelala C, Pereira SP, Kocher HM, Young BD, Bond-Smith G, Hitchens R, Cmogorau-Jurcveic T. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. *Am J Cancer Res* 2015; 5: 3455-3466 [PMID: 26807325]

51 Li A, Yu J, Kim H, Wolfgang CL, Canto MJ, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. *Clin Cancer Res* 2013; 19: 3600-3610 [PMID: 23697990 DOI: 10.1186/1078-0432.CCR-12-3092]

52 Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. *PLoS One* 2009; 4: e6816 [PMID: 19714243 DOI: 10.1371/journal.pone.0006816]
63 Sicard F, Gayral M, Liluka H, Buscall L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther 2013; 21: 986-994 [PMID: 23841526 DOI: 10.1038/mi.2013.35]

64 Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett 2014; 344: 166-173 [PMID: 24266610 DOI: 10.1016/j.canlet.2013.11.004]

65 Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010; 70: 5226-5237 [PMID: 20551052 DOI: 10.1158/0008-5472.CAN-09-2427]

66 Ali S, Ahmad A, Banerjee S, Padhye S, Dominik K, Schaaffert JM, Wang Z, Philip PA, Sarkar FH. Gemmacta sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-3617 [PMID: 20388782 DOI: 10.1158/0008-5472.CAN-09-4598]

67 Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-900 [PMID: 19945575 DOI: 10.1016/j.cell.2009.11.007]

68 Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firit E, Wellner U, Dimmler A, Faller G, Schubert J, Brabletz T. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011; 30: 770-782 [PMID: 21224848 DOI: 10.1038/emboj.2010.349]

69 Burk U, Schubert J, Wellner U, Schnallhoefer O, Viscaino E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589 [PMID: 18434366 DOI: 10.1038/embr.2008.74]

70 Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ, Ahmed A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH. Gemmacta sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-3617 [PMID: 20388782 DOI: 10.1158/0008-5472.CAN-09-4598]

71 TCGA databank. Available from: URL: http://cancergenome.nih.gov/
O’Hare P, Brabant G. Free leptin, bound leptin, and soluble leptin receptor in normal and diabetic pregnancies. *J Clin Endocrinol Metab* 1999; 84: 300-306 [PMID: 9920099 DOI: 10.1210/jcem.84.1.5401]

Harbuzariu A, Ranuppoldi A, Daley-Brown DS, Candalaria P, Harmon TL, Lipsey CC, Beech DJ, Quasrhue A, Ilies GO, Gonzalez-Perez RR. Leptin-Notch signaling axis is involved in pancreatic cancer progression. *Oncotarget* 2017; 8: 7740-7752 [PMID: 27999190 DOI: 10.18632/oncotarget.13946]

Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. *Biochim Biophys Acta* 2012; 1825: 207-222 [PMID: 22289790 DOI: 10.1016/j.bbcan.2012.01.002]

Stolzenberg-Solomon RZ, Newton CC, Silverman DT, Pollak M, Nogueira LM, Weinstein SJ, Albanes D, Männistö S, Jacobs EJ. Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. *Am J Epidemiol* 2015; 182: 187-197 [PMID: 26085045 DOI: 10.1093/aje/kvw041]

Pastar I, Khan AA, Stojadinovic O, Lebrun EA, Medina MC, Brem H, Kirnser RS, Jimenez JF, Lesicle C, Tonic-Canic M. Induction of specific microRNAs inhibits cutaneous wound healing. *J Biol Chem* 2012; 287: 29324-29335 [PMID: 22773832 DOI: 10.1074/jbc.M112.382135]

Derghal A, Djelloul M, Airlaut C, Pierre C, Dallaporta M, Troadec JD, Tillenent V, Tardivel C, Barishay B, Trouslard J, Mounien L. Leptin is required for hypothalamic regulation of miRNAs targeting POMC 3'UTR. *Front Cell Neurosci* 2015; 9: 172 [PMID: 25999818 DOI: 10.3389/fncel.2015.00172]

Kabra DG, Pfahlmann K, García-Cáceres C, Schriefer SC, Casquero García V, Kebede AF, Fuente-Martin E, Trivedi C, Heppner K, Uhlenhaut NH, Legutko B, Kabra UD, Gao Y, Yi CX, Quarta C, Clemmensen C, Finan B, Müller TD, Meyer CW, Paaz-Pereda M, Stemmer K, Woods SC, Perez-Tilve D, Schneider R, Olson EN, Tschöp MH, Pfluger PT. Hypothalamic leptin action is mediated by histone deacetylase 5. *Nat Commun* 2016; 7: 10782 [PMID: 26923837 DOI: 10.1038/ncomms10782]

Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Büchler M, Evert M, Lerch MM, Weiss FU. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. *Gut* 2012; 61: 439-448 [PMID: 22147512 DOI: 10.1136/gutjnl-2011-300060]

Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, Crucetru ML, Albulescu R. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. *World J Gastroenterol* 2014; 20: 10790-10801 [PMID: 25152582 DOI: 10.3748/wjg.v20.i31.10790]

Funato H, Oda S, Yokofujita J, Igarashi H, Kuroda M. Fasting and high-fat diet alter histone deacetylase expression in the medial hypothalamus. *PLoS One* 2011; 6: e18950 [PMID: 21526203]

Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. *Blood* 2011; 117: 2910-2917 [PMID: 21239696 DOI: 10.1182/blood-2010-08-303701]

P- Reviewer: Barreto S, Bilir C, Bramhall S  S- Editor: Kong JX  L- Editor: A  E- Editor: Lu YJ

Tchio Mantho CI et al. Pancreatic cancer and leptin crosstalk
